A new trial study has unearthed a wealth of evidence that suggest a powerful way to combat the crippling auto immune disease known as MS, otherwise known more properly as multiple sclerosis. The study was conducted at the National Institute of Allergy and Infectious Diseases and carried out under the purview of Dr. Richard Nash whose research found that 69 percent of all of the test patients experienced no relapses into MS nor any of the other symptoms common with the disability, such as bleeding of the brain. This is highly significant as the success rate of Dr. Shiva Gopal’s study was considerably higher than any normal, conventional MS treatment currently available.
The director of the National Institute of Allergy and Infectious Disease, Anthony Fauci, publicly stated that, “These extended findings suggest that one-time treatment with HDIT/HCT may be substantially more effective than long-term treatment with the best available medications for people with a certain type of MS. These encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.”
The study itself lasted five years and consisted of treating all of the patients with their own stem cells in a attempt to reset their immune systems. Then the test subjects are given high doses of chemotherapy to induce the immune system reset, simultaneously reintroducing the stem cells. Five years after the successful completion of the study the majority of the test subjects remained in remission. Additionally, many of the test subjects showed marked signs of increased mobility and a return of other previously debilitated physical capabilities.
Dr. Mikhail Blagosklonny is a well-known scientist. He has done many studies on cancer and aging. Moreover, Dr. Blagosklonny has developed unique concepts for cancer, biology, and therapy. Dr. Blagosklonny was a scholar at the First Pavlov State Medical University of St. Peterburg. He attained his M.D in Internal Medicine at the institution on LinkedIn. Dr. Blagosklonny also attained his Ph.D. in Cardiology and Experimental Medicine at the institution. In 2002, the New York Medical College, Valhalla appointed Dr. Blagosklonny as an Associate Professor of Medicine. After a while, he progressed in his career as a Senior Scientist at the Ordway Research Institute in Albany, New York. He is also the author of hyperfunction theory of aging and anti-cancer approaches known as chemotherapeutic engineering and cell cyclo-therapy on Google.
His field of interest is anti-aging medicine and oncology. Dr. Blagosklonny focuses on cancer and cancer therapies in-charge of protecting healthy cells from damage. He studies molecular and cellular biology and clinical investigation on Nature such as oncogenes, cell cycle, and signal transduction. Dr. Blagosklonny also researches on anti-aging drugs and biogerontology.
Dr. Mikhail Blagosklonny formulated a theory about TOR’s potential role in cancer and aging. He formulated this theory using Rapamycin, a drug used for cancer treatment to extend life. The scientist is known to advocate for the use of Rapamycin in longevity research. In addition to his research, Dr. Blagosklonny has published several research articles, book chapters, and reviews. He is the editor in chief of the Cell Cycle on tandfonline.com and co-founder and co-editor of oncotarget and oncoscience. Dr. Blagosklonny has also served as an associate editor for Cancer Biology and Therapy, Autophagy, Cancer Research, Cell Death and Differentiation, International Journal of Cancer, PLOS ONE, and The American Journal of Pathology.
Dr. Blagosklonny currently works at the Roswell Park Cancer Institute as a Professor of Oncology. He was appointed in 2009. The professor’s role is to facilitate the development of new anticancer strategies methods of cancer therapy and prevention. He has worked with the institute to implement their new ideas which include tissue-specific therapy of cancer, protection of healthy cells from radio and chemotherapy, selective combination of cancer drugs, and prevention of cancer by slowing down organismal aging.